Clinical Trials Logo
  1. Home
  2. Asthma
  3. NCT00532922
  4. Details
NCT00532922 Clinical Trial

A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Asthma Clinical Trial

— Symb NIS  

Official title:
A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00532922
Other study ID # NIS-RCN-SYM-2006/1
Secondary ID
Status Completed
Phase Phase 4
First received September 20, 2007
Last updated June 8, 2009
Start date April 2007
Est. completion date November 2007

Study information
Verified date June 2009
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Not required for this study:
Study type Observational

Clinical Trial Summary

The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.

Recruitment information / eligibility
Status Completed
Enrollment 310
Est. completion date November 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 6 Years and older
Eligibility Inclusion Criteria:

1. Provision of informed consent

2. Asthmatics who has been prescribed Symbicort according to physician's judgement

3. Usage of Symbicort should follow local prescribing information

Exclusion Criteria:

1. Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)

2. No previous enrolment in the present study

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
China Research Site Beijing
China Research Site Chengdu Sichuan
China Research Site Chongqing
China Research Site Fuzhou Fujian
China Research Site Guangzhou Guangdong
China Research Site Hangzhou
China Research Site Hefel Anhui
China Research Site Nanjong Jiangsu
China Research Site Qingdao Shandong
China Research Site Shanghai
China Research Site Shenyand Liaoning
China Research Site Shenzhen Guangdong
China Research Site Suzhou Jiangsu
China Research Site Taiyuan Shanxi
China Research Site Wenzhou Zhejiang
China Research Site Wuhan Hubei
China Research Site Wuhan Hubel
China Research Site Xi'an Shanxi
China Research Site Zhengzhou Henan

Sponsors (1)
Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

China, 

See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device